{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:45:25Z","timestamp":1790063125568,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Heart Foundation","award":["App ID: 100596- 2014"],"award-info":[{"award-number":["App ID: 100596- 2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40959-019-0046-5","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T19:05:37Z","timestamp":1566414337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cardiotoxicity after cancer treatment: a process map of the patient treatment journey"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-2618","authenticated-orcid":false,"given":"Robyn A.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania S.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchi","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Karapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogda","family":"Koczwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"issue":"4","key":"46_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.breast.2014.04.002","volume":"23","author":"F Ades","year":"2014","unstructured":"Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. Breast. 2014;23(4):317\u201328.","journal-title":"Breast"},{"issue":"24","key":"46_CR2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ETH Yeh","year":"2009","unstructured":"Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"46_CR3","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines\u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801.","journal-title":"Eur Heart J"},{"issue":"10","key":"46_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.hlc.2018.06.1042","volume":"27","author":"JJ Atherton","year":"2018","unstructured":"Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. 2018;27(10):1123\u2013208.","journal-title":"Heart Lung Circ"},{"issue":"8","key":"46_CR5","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.amjcard.2014.01.421","volume":"113","author":"C Chargari","year":"2014","unstructured":"Chargari C, Guy JB, Falk AT, Schouver ED, Trone JC, Moncharmont C, et al. Cardiotoxicity research in breast cancer patients: past and future. Am J Cardiol. 2014;113(8):1447\u20138.","journal-title":"Am J Cardiol"},{"issue":"3","key":"46_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"46_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ctrv.2010.08.007","volume":"37","author":"C Chargari","year":"2011","unstructured":"Chargari C, Kirov KM, Bollet MA, Magne N, Vedrine L, Cremades S, et al. Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev. 2011;37(4):321\u201330.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"46_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ctrv.2010.11.001","volume":"37","author":"E Senkus","year":"2011","unstructured":"Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300\u201311.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"46_CR9","first-page":"190","volume":"39","author":"I Daher","year":"2012","unstructured":"Daher I, Daigle T, Bhatia N, Durand J. The prevention of cardiovascular disease in cancer survivors. Tex Heart Inst J. 2012;39(2):190\u20138.","journal-title":"Tex Heart Inst J"},{"issue":"36","key":"46_CR10","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","volume":"28","author":"SA Jensen","year":"2010","unstructured":"Jensen SA, Hasbak P, Mortensen J, S\u00f8rensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol. 2010;28(36):5280\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"46_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","volume":"118","author":"C Lenneman","year":"2016","unstructured":"Lenneman C, Sawyer D. Cardio-oncology. Circ Res. 2016;118(6):1008\u201320.","journal-title":"Circ Res"},{"issue":"2","key":"46_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pcad.2010.06.005","volume":"53","author":"QS Wells","year":"2010","unstructured":"Wells QS, Lenihan DJ. Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Prog Cardiovasc Dis. 2010;53(2):140\u20138.","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"46_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.seminoncol.2013.01.008","volume":"40","author":"D Cardinale","year":"2013","unstructured":"Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla C. Strategies to prevent and treat cardiovaxcular risk in cancer patients. Semin Oncol. 2013;40(2):186\u201398.","journal-title":"Semin Oncol"},{"issue":"18","key":"46_CR14","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.2004.03.516","volume":"22","author":"Edith A. Perez","year":"2004","unstructured":"Perez EA, Suman VJ, Davidson NE, et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004;22:3700-4.","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"46_CR15","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739\u201391.","journal-title":"Eur Heart J"},{"key":"46_CR16","unstructured":"Nichols M, Peterson K, Alston L, Allender S. Australian heart disease statistics 2014. Melbourne: National Heart Foundation of Australia, Project; 2014."},{"issue":"2","key":"46_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdq609","volume":"22","author":"M Aapro","year":"2011","unstructured":"Aapro M, Bernard-Marty C, Brain EG, Batist G, Erdkamp F, Krzemieniecki K, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22(2):257\u201367.","journal-title":"Ann Oncol"},{"key":"46_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40959-017-0025-7","volume":"3","author":"RA Clark","year":"2017","unstructured":"Clark RA, Marin TS, Berry NM, Atherton JJ, Foote JW, Koczwara B. Cardiotoxicity and cardiovascular disease risk assessment for patients receiving breast cancer treatment. Cardio-Oncology. 2017;3:6.","journal-title":"Cardio-Oncology"},{"issue":"11","key":"46_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.echo.2017.06.025","volume":"30","author":"C Lorenzini","year":"2017","unstructured":"Lorenzini C, Lamberti C, Aquilina M, Rocca A, Cortesi P, Corsi C. Reliability of left ventricular ejection fraction from three-dimensional echocardiography for cardiotoxicity onset detection in patients with breast cancer. J Am Soc Echocardiogr. 2017;30(11):1103\u201310.","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"46_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pcad.2010.05.004","volume":"53","author":"DL Mann","year":"2010","unstructured":"Mann DL, Krone RJ. Cardiac disease in cancer patients: an overview. Prog Cardiovasc Dis. 2010;53(2):80\u20137.","journal-title":"Prog Cardiovasc Dis"},{"issue":"34","key":"46_CR21","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1200\/JCO.2005.02.5841","volume":"23","author":"JJ Doyle","year":"2005","unstructured":"Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23(34):8597\u2013605.","journal-title":"J Clin Oncol"},{"issue":"2","key":"46_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdq609","volume":"22","author":"M Aapro","year":"2010","unstructured":"Aapro M, Ryberg M, Soubeyran P, Wedding U, Bernard-Marty C, Brain EGC, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2010;22(2):257\u201367.","journal-title":"Ann Oncol"},{"issue":"2","key":"46_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pcad.2010.07.001","volume":"53","author":"JR Carver","year":"2010","unstructured":"Carver JR. Management of trastuzumab-related cardiac dysfunction. Prog Cardiovasc Dis. 2010;53(2):130\u20139.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"46_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1188\/08.ONF.909-915","volume":"35","author":"CC Hsieh","year":"2008","unstructured":"Hsieh CC, Sprod LK, Hydock DS, Carter SD, Hayward R, Schneider CM. Effects of a supervised exercise intervention on recovery from treatment regimens in breast cancer survivors. Oncol Nurs Forum. 2008;35(6):909\u201315.","journal-title":"Oncol Nurs Forum"},{"issue":"2","key":"46_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","volume":"53","author":"DB Sawyer","year":"2010","unstructured":"Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105\u201313.","journal-title":"Prog Cardiovasc Dis"},{"issue":"Spec Ed Integra","key":"46_CR26","first-page":"e192","volume":"12","author":"G Schrijvers","year":"2012","unstructured":"Schrijvers G, van Hoorn A, Huiskes N. The care pathway: concepts and theories: an introduction. Int J Integr Care. 2012;12(Spec Ed Integrated Care Pathways):e192.","journal-title":"Int J Integr Care"},{"key":"46_CR27","unstructured":"Institute for Patient- and Family-Centered Care. \n                    https:\/\/www.ipfcc.org\/\n                    \n                  . Accessed 29 May 2019."},{"issue":"Suppl 7","key":"46_CR28","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23(Suppl 7):vii155\u201366.","journal-title":"Ann Oncol"},{"key":"46_CR29","doi-asserted-by":"publisher","unstructured":"Campia U, Moslehi Javid J, Amiri-Kordestani L, Barac A, Beckman Joshua A, Chism David D, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation. Circulation. 2019;139:e579\u2013602. \n                    https:\/\/doi.org\/10.1161\/CIR.0000000000000641\n                    \n                  . Originally published 21 Feb 2019.","DOI":"10.1161\/CIR.0000000000000641"},{"key":"46_CR30","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1136\/bmj.c4078","volume":"341","author":"TM Trebble","year":"2010","unstructured":"Trebble TM, Hansi N, Hydes T, Smith MA, Baker M. Process mapping the patient journey: an introduction. BMJ. 2010;341:394\u2013401.","journal-title":"BMJ"},{"key":"46_CR31","unstructured":"Australian Institute of Health and Welfare 2018 Australian Government. Canberra. \n                    https:\/\/www.aihw.gov.au\/reports\/australias-health\/australias-health-2018\/contents\/table-of-contents\n                    \n                  . Accessed 30 July 2019."},{"issue":"3","key":"46_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.hfc.2011.03.007","volume":"7","author":"CL Chen","year":"2011","unstructured":"Chen CL, Steingart R. Cardiac disease and heart failure in cancer patients: is our training adequate to provide optimal care? Heart Fail Clin. 2011;7(3):357.","journal-title":"Heart Fail Clin"},{"issue":"11","key":"46_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/nrcardio.2015.133","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(11):620.","journal-title":"Nat Rev Cardiol"},{"key":"46_CR34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s11906-010-0146-y","volume":"12","author":"C Geisberg","year":"2010","unstructured":"Geisberg C, Sawyer D. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010;12:404\u201310.","journal-title":"Curr Hypertens Rep"},{"key":"46_CR35","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri M. Colombo Aea. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circ Res. 2004;109:2749\u201354.","journal-title":"Circ Res"},{"issue":"4","key":"46_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ehf2.12099","volume":"3","author":"VL Versace","year":"2016","unstructured":"Versace VL, Berry NM, Chowdhury MH, Ullah S, McCarthy AL, Atherton JJ, et al. Characteristics of patients with haematological and breast cancer (1996-2009) who died of heart failure-related causes after cancer therapy. Esc Heart Fail. 2016;3(4):253\u201360.","journal-title":"Esc Heart Fail"},{"issue":"1","key":"46_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1728-869X(11)60009-9","volume":"9","author":"D Hughes","year":"2011","unstructured":"Hughes D, Lenihan D, Harrison C, Basen-Engquist K. Exercise intervention for cancer survivors with heart failure: two case reports. J Exerc Sci Fit. 2011;9(1):65\u201373.","journal-title":"J Exerc Sci Fit"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-019-0046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40959-019-0046-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-019-0046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T19:23:25Z","timestamp":1597951405000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-019-0046-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1186\/s40959-019-0046-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was received for this project from the Southern Adelaide Clinical Human Research Ethics Committee (HREC) (#181.15); Metro South Health Service District HREC (#225.15), and Queensland University of Technology HREC (#445.15). Informed consent was received from each participant including consent to publish aggregated findings.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given final approval of the version to be published, take public responsibility for appropriate portions of the content, and have given final approval of this manuscript to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}